These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 22685174)

  • 1. Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1.
    Fang J; Rhyasen G; Bolanos L; Rasch C; Varney M; Wunderlich M; Goyama S; Jansen G; Cloos J; Rigolino C; Cortelezzi A; Mulloy JC; Oliva EN; Cuzzola M; Starczynowski DT
    Blood; 2012 Jul; 120(4):858-67. PubMed ID: 22685174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High basal nuclear levels of Nrf2 in acute myeloid leukemia reduces sensitivity to proteasome inhibitors.
    Rushworth SA; Bowles KM; MacEwan DJ
    Cancer Res; 2011 Mar; 71(5):1999-2009. PubMed ID: 21212410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.
    Colado E; Alvarez-Fernández S; Maiso P; Martín-Sánchez J; Vidriales MB; Garayoa M; Ocio EM; Montero JC; Pandiella A; San Miguel JF
    Haematologica; 2008 Jan; 93(1):57-66. PubMed ID: 18166786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p70S6 kinase is a target of the novel proteasome inhibitor 3,3'-diamino-4'-methoxyflavone during apoptosis in human myeloid tumor cells.
    Piedfer M; Bouchet S; Tang R; Billard C; Dauzonne D; Bauvois B
    Biochim Biophys Acta; 2013 Jun; 1833(6):1316-28. PubMed ID: 23481040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines.
    Liesveld JL; Rosell KE; Bechelli J; Lu C; Messina P; Mulford D; Ifthikharuddin JJ; Jordan CT; Phillips Ii GL
    Cancer Invest; 2011 Aug; 29(7):439-50. PubMed ID: 21740082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteasome inhibitor-induced apoptosis in acute myeloid leukemia: a correlation with the proteasome status.
    Matondo M; Bousquet-Dubouch MP; Gallay N; Uttenweiler-Joseph S; Recher C; Payrastre B; Manenti S; Monsarrat B; Burlet-Schiltz O
    Leuk Res; 2010 Apr; 34(4):498-506. PubMed ID: 19811823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myeloid malignancies with chromosome 5q deletions acquire a dependency on an intrachromosomal NF-κB gene network.
    Fang J; Barker B; Bolanos L; Liu X; Jerez A; Makishima H; Christie S; Chen X; Rao DS; Grimes HL; Komurov K; Weirauch MT; Cancelas JA; Maciejewski JP; Starczynowski DT
    Cell Rep; 2014 Sep; 8(5):1328-38. PubMed ID: 25199827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. XIAP downregulation promotes caspase-dependent inhibition of proteasome activity in AML cells.
    Carter BZ; Mak DH; Wang Z; Ma W; Mak PY; Andreeff M; Davis RE
    Leuk Res; 2013 Aug; 37(8):974-9. PubMed ID: 23669290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of panobinostat and marizomib in acute myeloid leukemia and bortezomib-resistant models.
    Corrales-Medina FF; Manton CA; Orlowski RZ; Chandra J
    Leuk Res; 2015 Mar; 39(3):371-9. PubMed ID: 25612941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.
    Saha MN; Jiang H; Jayakar J; Reece D; Branch DR; Chang H
    Cancer Biol Ther; 2010 Jun; 9(11):936-44. PubMed ID: 20418664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.
    Niewerth D; Kaspers GJ; Assaraf YG; van Meerloo J; Kirk CJ; Anderl J; Blank JL; van de Ven PM; Zweegman S; Jansen G; Cloos J
    J Hematol Oncol; 2014 Jan; 7():7. PubMed ID: 24418325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteasome inhibitor interacts synergistically with autophagy inhibitor to suppress proliferation and induce apoptosis in hepatocellular carcinoma.
    Hui B; Shi YH; Ding ZB; Zhou J; Gu CY; Peng YF; Yang H; Liu WR; Shi GM; Fan J
    Cancer; 2012 Nov; 118(22):5560-71. PubMed ID: 22517429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib sensitivity of acute myeloid leukemia CD34(+) cells can be enhanced by targeting the persisting activity of NF-κB and the accumulation of MCL-1.
    Bosman MC; Schuringa JJ; Quax WJ; Vellenga E
    Exp Hematol; 2013 Jun; 41(6):530-538.e1. PubMed ID: 23416210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib enhances radiosensitivity in oral cancer through inducing autophagy-mediated TRAF6 oncoprotein degradation.
    Wu YH; Wu WS; Lin LC; Liu CS; Ho SY; Wang BJ; Huang BM; Yeh YL; Chiu HW; Yang WL; Wang YJ
    J Exp Clin Cancer Res; 2018 Apr; 37(1):91. PubMed ID: 29703234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival.
    Corradi G; Baldazzi C; Očadlíková D; Marconi G; Parisi S; Testoni N; Finelli C; Cavo M; Curti A; Ciciarello M
    Stem Cell Res Ther; 2018 Oct; 9(1):271. PubMed ID: 30359303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.
    Kuhn DJ; Berkova Z; Jones RJ; Woessner R; Bjorklund CC; Ma W; Davis RE; Lin P; Wang H; Madden TL; Wei C; Baladandayuthapani V; Wang M; Thomas SK; Shah JJ; Weber DM; Orlowski RZ
    Blood; 2012 Oct; 120(16):3260-70. PubMed ID: 22932796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic effect of bortezomib and valproic acid treatment on the proliferation and apoptosis of acute myeloid leukemia and myelodysplastic syndrome cells.
    Wang AH; Wei L; Chen L; Zhao SQ; Wu WL; Shen ZX; Li JM
    Ann Hematol; 2011 Aug; 90(8):917-31. PubMed ID: 21340723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An autophagy inhibitor enhances the inhibition of cell proliferation induced by a proteasome inhibitor in MCF-7 cells.
    Yao F; Wang G; Wei W; Tu Y; Tong H; Sun S
    Mol Med Rep; 2012 Jan; 5(1):84-8. PubMed ID: 21931937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim.
    Nikrad M; Johnson T; Puthalalath H; Coultas L; Adams J; Kraft AS
    Mol Cancer Ther; 2005 Mar; 4(3):443-9. PubMed ID: 15767553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5.
    Zhu YX; Tiedemann R; Shi CX; Yin H; Schmidt JE; Bruins LA; Keats JJ; Braggio E; Sereduk C; Mousses S; Stewart AK
    Blood; 2011 Apr; 117(14):3847-57. PubMed ID: 21289309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.